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SUPPLEMENTARY NOTES
ABSTRACT
I discovered that cap-independent translation of oncogene mRNAs, e.g. c-myc or vascular endothelial growth factor (VEGF) transcripts, is regulated by affinity of the eukaryotic initiation factor (eIF4G) for sequences within the 5' untranslated region of such mRNAs. Our work contributes to understanding how translation initiation factors, phosphoproteins controlled by the major oncogenic signaling pathways in cancer, regulate gene expression at the translational level. My findings enable functional studies of eIF4G and how it responds to protein kinase inhibitors currently tested in cancer therapy, e.g. against breast cancer. Most importantly, my work contributes key empirical evidence in support of a novel experimental cancer treatment scheduled to enter clinical investigation within the next 6 months. Cell type specific cancer cell killing of the prototype oncolytic poliovirus, PVS-RIPO, depends on selective eIF4G:IRES binding in cancerous cells. My work provided the empirical basis behind this principle and constitutes a critical aspect of correlative studies demanded by FDA.
SUBJECT TERMS
Translation, eIF4E, eIF4G, IRES, Cancer, Poliovirus (Dobrikova et al., 2006) . I was further involved with studies of translation regulation via the eIF4G-binding partner poly-adenylate binding protein (PABP) (Bradrick et al., 2007) . Most importantly, the bulk of my thesis work revealed eIF4G's role in regulating cap-independent translation initiation at oncogene mRNAs, e.g. c-myc and the vascular endothelial growth factor (VEGF) (Kaiser et al., 2008) .
Key Research Accomplishments:
• Elucidation of cis-acting elements contributing to c-myc mRNA translation control 
